Information regarding the generic availability of Tresiba FlexTouch is limited.
When might Tresiba FlexTouch go off-patent?
The patent expiration dates for Tresiba FlexTouch and its active ingredient, insulin degludec, are key to determining when generic versions could become available. Patent information can be complex and may vary by region. DrugPatentWatch.com tracks these patent and exclusivity details. [1]
What is Tresiba FlexTouch used for?
Tresiba FlexTouch is a brand-name prescription medication used to improve glycemic control in adults and children aged 1 year and older with diabetes mellitus. It is an injectable long-acting insulin. [2]
How does Tresiba FlexTouch work?
Tresiba FlexTouch contains insulin degludec, which is a basal (long-acting) insulin. It works by lowering blood glucose levels. Insulin degludec has an ultra-long duration of action, meaning it is released slowly into the bloodstream over an extended period. [3]
What are the potential side effects of Tresiba FlexTouch?
Common side effects of Tresiba FlexTouch can include low blood sugar (hypoglycemia), allergic reactions, injection site reactions, and changes in body weight. Serious side effects may include severe hypoglycemia and hypokalemia (low potassium levels). [2]
How is Tresiba FlexTouch administered?
Tresiba FlexTouch is administered via subcutaneous injection. The FlexTouch is a prefilled pen device designed for easier self-injection. [2]
What is the difference between Tresiba and other insulins?
Tresiba (insulin degludec) is a basal insulin with an ultra-long duration of action, distinguishing it from other basal insulins like insulin glargine or insulin detemir, which have shorter durations. This ultra-long action can offer more flexibility in dosing timing. [3]
Who manufactures Tresiba FlexTouch?
Tresiba FlexTouch is manufactured by Novo Nordisk. [4]
Are there other forms of insulin degludec available?
Insulin degludec is also available in combination with other insulins, such as insulin aspart, under different brand names. [5]
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.tresiba.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597136/
[4] https://www.novonordisk.com/
[5] https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/types-insulin